Efficacy and safety of glycoprotein IIb / IIIa inhibitors in addition to P2Y 12 inhibitors in ST ‐segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial-Reference-Cited by-同舟云学术

Efficacy and safety of glycoprotein IIb / IIIa inhibitors in addition to P2Y 12 inhibitors in ST ‐segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial

Published:2021-07-07 Issue: Volume: Page:
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Cathet Cardio Intervent

Author:

Tavenier Anne H.¹^ORCID,Claassens Daniel M. F.¹²,Hermanides Renicus S.¹,Vos Gerrit J. A.²,Bergmeijer Thomas O.²,Kelder Johannes C.²,Deneer Vera H. M.³⁴,van 't Hof Arnoud W. J.¹⁵⁶⁷,ten Berg Jurriën M.²⁶^ORCID

Affiliation:

1. Department of Cardiology Isala Hospital Zwolle The Netherlands

2. Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands

3. Department of Clinical Pharmacy St. Antonius Hospital Nieuwegein The Netherlands

4. Department of Clinical Pharmacy University Medical Center Utrecht Utrecht The Netherlands

5. Department of Cardiology University Medical Center Maastricht Maastricht The Netherlands

6. Cardiovascular Research Institute Maastricht (CARIM) Maastricht The Netherlands

7. Department of Cardiology Zuyderland Medical Center Heerlen The Netherlands

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccd.29861

Reference30 articles.

1. Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study

2. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion ? results of the Austrian multi-centre randomized ReoPro-BRIDGING Study

3. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis

4. Early vs Late Administration of Glycoprotein IIb/IIIa Inhibitors in Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction

5. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Future Roles of Glycoprotein IIb–IIIa Inhibitors in Primary Angioplasty for ST-Segment Elevation Myocardial Infarction;Biomedicines;2024-09-04

2. A dual-center analysis of conservative versus liberal glycoprotein IIb–IIIa antagonist strategies in the treatment of ST-elevation myocardial infarction;Scientific Reports;2024-07-01

3. Association of Glycoprotein IIIa PlA1/A2 Polymorphism with Risk of Stroke: Updated Meta-Analysis;Current Issues in Molecular Biology;2024-05-28

4. Conservative vs. Liberal Glycoprotein IIb-IIIa Antagonist Strategies in the Treatment of ST-Elevation Myocardial Infarction: A Dual-Center Analysis;2024-01-10

5. DAPT and GPVI: an antiplatelet triple threat;Journal of Thrombosis and Haemostasis;2023-11